Journal of Turkish Clinical Biochemistry

The official publication of Turkish Society of Clinical Biochemistry

Diamond OA
No APCs
First Decision
30 Days
Indexed In
TR Dizin
Case Report
April 01, 2013
JTCB. 2013 Apr 1; 11 (1) : 031-035

C282y/H63d Mutation In A Patient with Iron Overload: A Case of Hereditary Hemochromatosis

1 Akdeniz Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Antalya

Abstract

Hereditary hemochromatosis (HH) is a genetic disorder of iron metabolism which leads to irregular iron absorption from the intestine and iron overload in patients diagnosed with the disease. The majority of patients with clinical iron overload are homozygous for the C282Y mutation in the HFE gene, however C282Y/H63D heterozygosities are reported in some patients. In this study, we report a case of compound heterozygosity (C282Y/H63D) in the HFE gene.C282Y and H63D mutations were evaluated via 5' nuclease real time PCR analysis. Serum ferritin was measured by electro-chemiluminescence immunoassay while transferrin was determined via nepholometric method. Other biochemical parameters were measured by Roche Hitachi Cobas 8000 Modular Analyzer.The patient had increased serum ferritin and transferrin saturation. C282Y/H63D compound heterozygote mutations were determined in the patient that was subsequently diagnosed with hereditary hemochromatosis.

Conclusion: Screening of HFE mutations in all patients and first degree relatives that have increased serum ferritin and transferrin saturation will enable the diagnosis of HH.

Citation

Aslan, Mutay. 2013. “C282y/H63d/Mutation/In/A/Patient/With/Iron/Overload:/A/Case/of/Hereditary/Hemochromatosis”. Journal of Turkish Clinical Biochemistry 11 (1):031-035. https://turkclinbiochem.org/index.php/pub/article/view/180.

Publish with JTCB

Diamond Open Access

Fully Diamond OA with no APCs and no submission fees. Your research is freely available to readers worldwide from the day it publishes.

30-Day First Decision

Double-blind peer review from an active editorial team returns a first decision in about 30 days, keeping your manuscript moving.

Global Platform

Backed by the Turkish Society of Clinical Biochemistry, JTCB welcomes submissions from researchers worldwide and reaches an international laboratory audience.

Focused Laboratory Scope

Method validation, analyzer comparisons, reference intervals, quality indicators, preanalytical studies, and instructive clinical case reports.

Credible and Discoverable

All manuscripts publish in English and follow ICMJE and COPE guidelines, with Crossref DOIs and TR Dizin indexing ensuring global discoverability.